RestructuringApr 4, 2026, 07:44 AM
FibroBiologics Implements 1-for-20 Reverse Stock Split
AI Summary
FibroBiologics implemented a 1-for-20 reverse stock split of its common stock, effective March 30, 2026. This action reduces the number of outstanding shares and proportionally adjusts equity incentive plans and outstanding options/warrants, but does not alter stockholders' percentage ownership (except for fractional share adjustments).
Key Highlights
- Implemented a 1-for-20 reverse stock split effective March 30, 2026.
- CUSIP number changed to 31573L204, trading symbol remains FBLG.
- Fractional shares will be rounded up to the nearest whole share.
- Equity incentive plans and outstanding options/warrants are proportionately adjusted.